The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions

Filippo Gagliardi, Ashwin Narayanan, Michele Reni, Alberto Franzin, Elena Mazza, Nicola Boari, Michele Bailo, Paola Zordan, Pietro Mortini

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Given the extensive histomorphological heterogeneity of high-grade gliomas, in terms of extent of invasiveness, angiogenesis, and necrosis and the poor prognosis for patients despite the advancements made in therapeutic management. The identification of genes associated with these phenotypes will permit a better definition of glioma heterogeneity, which may ultimately lead to better treatment strategies. CXCR4, a cell surface chemokine receptor, is implicated in the growth, invasion, angiogenesis and metastasis in a wide range of malignant tumors, including gliomas. It is overexpressed in glioma cells according to tumor grade and in glioma tumor initiating cells. There have been various reports suggesting that CXCR4 is required for tumor proliferation, invasion, angiogenesis, and modulation of the immune response. It may also serve as a prognostic factor in characterizing subsets of glioblastoma multiforme, as patients with CXCR4-positive gliomas seem to have poorer prognosis after surgery. Aim of this review was to analyze the current literature on biological effects of CXCR4 activity and its role in glioma pathogenesis. A better understanding of CXCR4 pathway in glioma will lead to further investigation of CXCR4 as a novel putative therapeutic target.

Original languageEnglish
Pages (from-to)1015-1023
Number of pages9
JournalGLIA
Volume62
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Glioma
Neoplasms
Neoplastic Stem Cells
Direction compound
Chemokine Receptors
Cell Surface Receptors
Glioblastoma
Necrosis
Therapeutics
Neoplasm Metastasis
Phenotype
Growth
Genes

Keywords

  • Brain tumor
  • Cancer stem cells
  • Chemokine receptor

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Neurology
  • Medicine(all)

Cite this

The role of CXCR4 in highly malignant human gliomas biology : Current knowledge and future directions. / Gagliardi, Filippo; Narayanan, Ashwin; Reni, Michele; Franzin, Alberto; Mazza, Elena; Boari, Nicola; Bailo, Michele; Zordan, Paola; Mortini, Pietro.

In: GLIA, Vol. 62, No. 7, 2014, p. 1015-1023.

Research output: Contribution to journalArticle

Gagliardi, F, Narayanan, A, Reni, M, Franzin, A, Mazza, E, Boari, N, Bailo, M, Zordan, P & Mortini, P 2014, 'The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions', GLIA, vol. 62, no. 7, pp. 1015-1023. https://doi.org/10.1002/glia.22669
Gagliardi, Filippo ; Narayanan, Ashwin ; Reni, Michele ; Franzin, Alberto ; Mazza, Elena ; Boari, Nicola ; Bailo, Michele ; Zordan, Paola ; Mortini, Pietro. / The role of CXCR4 in highly malignant human gliomas biology : Current knowledge and future directions. In: GLIA. 2014 ; Vol. 62, No. 7. pp. 1015-1023.
@article{880301c4781f48f49d6b70fe9679ad8a,
title = "The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions",
abstract = "Given the extensive histomorphological heterogeneity of high-grade gliomas, in terms of extent of invasiveness, angiogenesis, and necrosis and the poor prognosis for patients despite the advancements made in therapeutic management. The identification of genes associated with these phenotypes will permit a better definition of glioma heterogeneity, which may ultimately lead to better treatment strategies. CXCR4, a cell surface chemokine receptor, is implicated in the growth, invasion, angiogenesis and metastasis in a wide range of malignant tumors, including gliomas. It is overexpressed in glioma cells according to tumor grade and in glioma tumor initiating cells. There have been various reports suggesting that CXCR4 is required for tumor proliferation, invasion, angiogenesis, and modulation of the immune response. It may also serve as a prognostic factor in characterizing subsets of glioblastoma multiforme, as patients with CXCR4-positive gliomas seem to have poorer prognosis after surgery. Aim of this review was to analyze the current literature on biological effects of CXCR4 activity and its role in glioma pathogenesis. A better understanding of CXCR4 pathway in glioma will lead to further investigation of CXCR4 as a novel putative therapeutic target.",
keywords = "Brain tumor, Cancer stem cells, Chemokine receptor",
author = "Filippo Gagliardi and Ashwin Narayanan and Michele Reni and Alberto Franzin and Elena Mazza and Nicola Boari and Michele Bailo and Paola Zordan and Pietro Mortini",
year = "2014",
doi = "10.1002/glia.22669",
language = "English",
volume = "62",
pages = "1015--1023",
journal = "GLIA",
issn = "0894-1491",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - The role of CXCR4 in highly malignant human gliomas biology

T2 - Current knowledge and future directions

AU - Gagliardi, Filippo

AU - Narayanan, Ashwin

AU - Reni, Michele

AU - Franzin, Alberto

AU - Mazza, Elena

AU - Boari, Nicola

AU - Bailo, Michele

AU - Zordan, Paola

AU - Mortini, Pietro

PY - 2014

Y1 - 2014

N2 - Given the extensive histomorphological heterogeneity of high-grade gliomas, in terms of extent of invasiveness, angiogenesis, and necrosis and the poor prognosis for patients despite the advancements made in therapeutic management. The identification of genes associated with these phenotypes will permit a better definition of glioma heterogeneity, which may ultimately lead to better treatment strategies. CXCR4, a cell surface chemokine receptor, is implicated in the growth, invasion, angiogenesis and metastasis in a wide range of malignant tumors, including gliomas. It is overexpressed in glioma cells according to tumor grade and in glioma tumor initiating cells. There have been various reports suggesting that CXCR4 is required for tumor proliferation, invasion, angiogenesis, and modulation of the immune response. It may also serve as a prognostic factor in characterizing subsets of glioblastoma multiforme, as patients with CXCR4-positive gliomas seem to have poorer prognosis after surgery. Aim of this review was to analyze the current literature on biological effects of CXCR4 activity and its role in glioma pathogenesis. A better understanding of CXCR4 pathway in glioma will lead to further investigation of CXCR4 as a novel putative therapeutic target.

AB - Given the extensive histomorphological heterogeneity of high-grade gliomas, in terms of extent of invasiveness, angiogenesis, and necrosis and the poor prognosis for patients despite the advancements made in therapeutic management. The identification of genes associated with these phenotypes will permit a better definition of glioma heterogeneity, which may ultimately lead to better treatment strategies. CXCR4, a cell surface chemokine receptor, is implicated in the growth, invasion, angiogenesis and metastasis in a wide range of malignant tumors, including gliomas. It is overexpressed in glioma cells according to tumor grade and in glioma tumor initiating cells. There have been various reports suggesting that CXCR4 is required for tumor proliferation, invasion, angiogenesis, and modulation of the immune response. It may also serve as a prognostic factor in characterizing subsets of glioblastoma multiforme, as patients with CXCR4-positive gliomas seem to have poorer prognosis after surgery. Aim of this review was to analyze the current literature on biological effects of CXCR4 activity and its role in glioma pathogenesis. A better understanding of CXCR4 pathway in glioma will lead to further investigation of CXCR4 as a novel putative therapeutic target.

KW - Brain tumor

KW - Cancer stem cells

KW - Chemokine receptor

UR - http://www.scopus.com/inward/record.url?scp=84900816115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900816115&partnerID=8YFLogxK

U2 - 10.1002/glia.22669

DO - 10.1002/glia.22669

M3 - Article

C2 - 24715652

AN - SCOPUS:84900816115

VL - 62

SP - 1015

EP - 1023

JO - GLIA

JF - GLIA

SN - 0894-1491

IS - 7

ER -